Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.55 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.53 |
| ▸ | TSHR | P16473 | 2/20 | 0.50 |
| ▸ | PLAU | P00749 | 1/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.44 |
| ▸ | CTSD | P07339 | 1/20 | 0.44 |
| ▸ | CXCL8 | P10145 | 1/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.41 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.41 |
| ▸ | F2 | P00734 | 1/20 | 0.41 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.41 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.41 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29688451 | 1.00 | ALDH1A1 (0.55) | ALDH1A1CYP1A2TSHRPLAUHSD17B10 | |
| SCHEMBL27474823 | 0.86 | ALDH1A1 (0.58) | ALDH1A1CYP1A2TSHRHSD17B10CTSD | |
| SCHEMBL3003307 | 0.84 | ALDH1A1 (0.57) | ALDH1A1CYP1A2TSHRHSD17B10CTSD | |
| SCHEMBL2431833 | 0.84 | CYP1A2 (0.63) | ALDH1A1CYP1A2TSHRHSD17B10TDP1 | |
| SCHEMBL2431836 | 0.84 | CYP1A2 (0.63) | ALDH1A1CYP1A2TSHRHSD17B10TDP1 | |
| SCHEMBL7895205 | 0.83 | ALDH1A1 (0.56) | ALDH1A1CYP1A2TSHRPLAUHSD17B10 | |
| SCHEMBL27935952 | 0.83 | ALDH1A1 (0.52) | ALDH1A1CYP1A2TSHRPLAUHSD17B10 | |
| SCHEMBL2413159 | 0.83 | ALDH1A1 (0.55) | ALDH1A1CYP1A2TSHRHSD17B10CTSD | |
| SCHEMBL7733065 | 0.83 | CYP1A2 (0.57) | ALDH1A1CYP1A2TSHRHSD17B10CTSD | |
| SCHEMBL974764 | 0.83 | ALDH1A1 (0.55) | ALDH1A1CYP1A2TSHRHSD17B10TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 61 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111825611-B | 4(1H) -quinovone derivatives and uses thereof | 刘扶东 | 2022-09-09 | — | — | CN | disclosed |
| CN-115003703-A | Hyaluronic acid derivatives | 麻省理工学院 | 2022-09-02 | — | — | CN | disclosed |
| CN-111116451-A | Polysubstituted tryptophane benzamide compound and preparation method and application thereof | 宁波大学 | 2020-05-08 | — | — | CN | disclosed |
| EP-3333165-B1 | PIPERAZINE DERIVATIVE | ASTELLAS PHARMA INC (JP) | 2019-09-18 | — | — | EP | disclosed |
| EP-3333165-A1 | PIPERAZINE DERIVATIVE | Astellas Pharma Inc. (JP) | 2018-06-13 | — | — | EP | disclosed |
| EP-2067770-B1 | PROCESS FOR PRODUCTION OF SULFONIC ACID ESTER | WAKO PURE CHEM IND LTD (JP) | 2017-04-12 | — | — | EP | disclosed |
| CN-104640844-B | The preparation method of 4-amino-5-fluorine-3-halo-6-(substituted) pyridine-2-formic acid esters | 美国陶氏益农公司 | 2016-11-09 | — | — | CN | disclosed |
| US-20150366885-A1 | TRIAZOLE COMPOUNDS THAT MODULATE HSP90 ACTIVITY | SYNTA PHARMACEUTICALS CORP (US) | 2015-12-24 | — | — | US | disclosed |
| US-9206162-B2 | Triazole compounds that modulate Hsp90 activity | SYNTA PHARMACEUTICALS CORP. (US) | 2015-12-08 | — | — | US | disclosed |
| US-20150266858-A1 | TRIAZOLE COMPOUNDS THAT MODULATE HSP90 ACTIVITY | LSI FINANCING LLC, AS ADMINISTRATIVE AGENT | 2015-09-24 | — | — | US | disclosed |
| US-20080269213-A1 | 8-Hydroxyquinoline compounds and methods thereof | WYETH (US) | 2008-10-30 | — | — | US | disclosed |
| WO-2008103353-A1 | TRIAZOLE COMPOUNDS THAT MODULATE HSP90 ACTIVITY | SYNTA PHARMACEUTICALS CORP. (US) | 2008-08-28 | — | — | WO | disclosed |
| WO-2008097640-A2 | TRIAZOLE COMPOUNDS THAT ARE USEFUL IN THE TREATMENT OF PROLIFERATIVE DISORDERS, SUCH AS CANCER | SYNTA PHARMACEUTICALS CORP. (US) | 2008-08-14 | — | — | WO | disclosed |
| US-20080176840-A1 | e.g. 4-(4-(6-(N-(2-methoxyethyl)-N-methylamino)pyridin-3-yl)-5-hydroxy-4H-1,2,4-triazol-3-yl)-6-isopropylbenzene-1,3-diol; Heat Shock Protein 90 (HSP90) modulator; antiproliferative, anticarcinogenic, antiinflammatory agent; angiogenesis inhibition, infections | SYNTA PHARMACEUTICALS CORP | 2008-07-24 | — | — | US | disclosed |
| EP-1928846-A2 | TRIAZOLE COMPOUNDS THAT MODULATE HSP90 ACTIVITY | Synta Pharmaceuticals Corporation (US) | 2008-06-11 | — | — | EP | disclosed |
| US-20080090887-A1 | Heat Shock Protein 90 (HSP90); treating cancer, inflammatory disorders, angiogenesis inhibition, infections; 3-substituted-4-fused(hetero)aryl-5-phenyl-4H-1,2,4-triazoles | SYNTA PHARMACEUTICALS CORP. | 2008-04-17 | — | — | US | disclosed |
| WO-2007139967-A2 | TRIAZOLE COMPOUNDS THAT MODULATE HSP90 ACTIVITY | SYNTA PHARMACEUTICALS CORP. (US) | 2007-12-06 | — | — | WO | disclosed |
| WO-2007139955-A2 | TRIAZOLE COMPOUNDS THAT MODULATE HSP90 ACTIVITY | SYNTA PHARMACEUTICALS CORP. (US) | 2007-12-06 | — | — | WO | disclosed |
| WO-2007094819-A2 | TRIAZOLE COMPOUNDS THAT MODULATE HSP90 ACTIVITY | SYNTA PHARMACEUTICALS CORP. (US) | 2007-08-23 | — | — | WO | disclosed |
| US-20070155809-A1 | Triazole compounds that modulate HSP90 activity | LSI FINANCING LLC, AS ADMINISTRATIVE AGENT | 2007-07-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080090887-A1 | Heat Shock Protein 90 (HSP90); treating cancer, inflammatory disorders, angiogenesis inhibition, infections; 3-substituted-4-fused(hetero)aryl-5-phenyl-4H-1,2,4-triazoles | HSP90AB1, HSP90AA1, HSP90AB2P | ALDH1A1 2241/4885CYP1A2 2470/4885TSHR 4210/4885 |
| US-20070155809-A1 | Triazole compounds that modulate HSP90 activity | HSP90AB1, HSP90B1, HSP90AA1 | ALDH1A1 2165/4885CYP1A2 1914/4885TSHR 4046/4885 |
| US-20080269213-A1 | 8-Hydroxyquinoline compounds and methods thereof | MMP8, MMP26, MMP9 | ALDH1A1 406/4885CYP1A2 763/4885TSHR 1695/4885 |
| US-20150366885-A1 | TRIAZOLE COMPOUNDS THAT MODULATE HSP90 ACTIVITY | HSP90AB1, HSP90B1, HSP90AA1 | ALDH1A1 2165/4885CYP1A2 1914/4885TSHR 4046/4885 |
| US-20080176840-A1 | e.g. 4-(4-(6-(N-(2-methoxyethyl)-N-methylamino)pyridin-3-yl)-5-hydroxy-4H-1,2,4-triazol-3-yl)-6-isopropylbenzene-1,3-diol; Heat Shock Protein 90 (HSP90) modulator; antiproliferative, anticarcinogenic, antiinflammatory agent; angiogenesis inhibition, infections | HSP90AB1, HSP90AB2P, HSP90B1 | ALDH1A1 1933/4885CYP1A2 2149/4885TSHR 4560/4885 |
| US-20150266858-A1 | TRIAZOLE COMPOUNDS THAT MODULATE HSP90 ACTIVITY | HSP90AB1, HSP90B1, HSP90AA1 | ALDH1A1 2165/4885CYP1A2 1914/4885TSHR 4046/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.